Tech Company Financing Transactions

EpiBiologics Funding Round

Codon Capital, Digitalis Ventures and GV participated in a $23 million Series A capital raise for EpiBiologics. The funding round was announced on 7/20/2023.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

1900 Alameda de las Pulgas 250
San Mateo, CA 94403
USA

Phone

Undisclosed

Website

www.epibiologics.com

Email Address

[email protected]

Overview

We are a venture backed company with a mission to develop first-in-class and best-in-class antibody based targeted therapies against membrane and extracellular proteins that drive underlying disease biology. Protein degradation has the potential to eliminate disease causing proteins that were previously not addressable by classical therapeutic approaches. First generation protein degradation approaches can degrade intracellular proteins but do not address membrane and extracellular proteins, which are approximately 40% of the proteome.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Rami Hannoush

        

Chief Financial Officer

Mitchell Mutz

        

Chief Operating Officer

Craig Lichtenstein

        

Chief Scientific Officer

Shyra Gardai

        

Browse more venture capital transactions:

Prev: 7/20/2023: Cleanlab venture capital transaction
Next: 7/20/2023: IMPACT+ venture capital transaction

Share this article

News on VC Transactions

We do our best to document funding rounds that are announced publicly. VC transactions reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary